Medtronic Hit With Shareholder Suit Over Infuse Studies

Law360, New York (June 28, 2013, 6:01 PM EDT) -- Medical device maker Medtronic Inc. helped researchers downplay the risks and side effects of its Infuse bone graft product, causing its stock price to fall when the scheme was revealed, a Minnesota securities class action filed Thursday alleges.

Minneapolis-based Medtronic allegedly worked with some researchers to hide Infuse's risks and then didn't disclose that when those risks were revealed surgeons would stop using it as much, inflating and then bringing the company's stock price down from 2010 to 2011, according to a complaint filed by the...
To view the full article, register now.

Documents

Related

Sections

Case Information

Case Title

West Virginia Pipe Trades Health & Welfare Fund v. Medtronic, Inc. et al


Case Number

0:13-cv-01686

Court

Minnesota

Nature of Suit

Securities/Commodities

Judge

John R. Tunheim

Date Filed

June 27, 2013

Law Firms

Companies

Government Agencies

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.